Nycomed Wins Contrast Media Agreement In USA
Norwegian health care company Nycomed, which specializes in imagingagents and pharmaceuticals, has announced that its US-based operation, Nycomed Inc, has been awarded an agreement to provide University HealthSystem Consortium Services Corp's purchasing participants with its line of contrast media products for both X-ray and magnetic resonance imaging.
UHCSC, a group-purchasing organization for about 100 academic health centers in the USA, has been working in partnership with Nycomed since 1991, during which time the latter has supplied its customers with Omnipaque (iohexol) as well as Visipaque (iodixanol) products for X-ray procedures.
The new, three-year agreement, which begins January 1, 1998, has been expanded to include Omniscan (gadodiamide), an intravenous contrast agent. The deal is designed to reward customers who use all of Nycomed's contrast media products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze